Efficacy and safety at 6 months of the XEN implant for the management of open angle glaucoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 03 2020
11 03 2020
Historique:
received:
02
12
2019
accepted:
18
02
2020
entrez:
13
3
2020
pubmed:
13
3
2020
medline:
21
11
2020
Statut:
epublish
Résumé
The purpose of this study is to evaluate the efficacy and complications of the XEN implant as a solo procedure or in association with cataract surgery in patients with open angle glaucoma (OAG). All patients who received a XEN implant between June 2017 and June 2018 were included in the study. The primary and secondary outcomes were: the reduction of the intraocular pressure (IOP) at 6 months postoperatively, the decrease of the glaucoma medications 6 months after surgery, the clinical success rate (eyes (%) achieving ≥20% IOP reduction on the same or fewer medications without secondary surgical intervention), the frequency and type of postoperative interventions as well as the complication rate. We included one hundred and seven eyes from 97 patients with primary OAG (79%), or secondary OAG (21%). Seventy-seven patients (72%) received a standalone XEN implantation and 30 (28%) underwent XEN implantation combined with phacoemusification. The IOP decreased from 20.4 mm Hg ± 6.4 preoperatively to 15.4 mm Hg ± 5.3 six months after the surgery, which represented a reduction of 24.5% (P = 1.4.10
Identifiants
pubmed: 32161332
doi: 10.1038/s41598-020-61319-1
pii: 10.1038/s41598-020-61319-1
pmc: PMC7066242
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4527Références
Kingman, S. Glaucoma is second leading cause of blindness globally. Bull. World Health Organ. 82, 887–888 (2004).
pubmed: 15640929
pmcid: 2623060
Tham, Y.-C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121, 2081–2090 (2014).
doi: 10.1016/j.ophtha.2014.05.013
Heijl, A. et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120, 1268–1279 (2002).
doi: 10.1001/archopht.120.10.1268
Kass, M. A. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120(701–713; discussion), 829–830 (2002).
The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am. J. Ophthalmol. 130, 429–440 (2000).
doi: 10.1016/S0002-9394(00)00538-9
Hamard, P. Open-angle glaucoma and surgical treatment. EMC Volume 13 (2016).
Gedde, S. J. et al. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up. Ophthalmology 125, 650–663 (2018).
doi: 10.1016/j.ophtha.2018.02.003
Kirwan, J. F. et al. Trabeculectomy in the 21st Century: A Multicenter Analysis. Ophthalmology 120, 2532–2539 (2013).
doi: 10.1016/j.ophtha.2013.07.049
Richter, G. M. & Coleman, A. L. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol 10, 189–206 (2016).
pubmed: 26869753
pmcid: 4734795
American Glaucoma Society. AGS and FDA MIGS Workshop. (2014).
Widder, R. A. et al. The XEN45 Gel Stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profile, and rates of re-surgery after 261 surgeries. Graefes Arch. Clin. Exp. Ophthalmol., https://doi.org/10.1007/s00417-018-3899-7 (2018).
doi: 10.1007/s00417-018-3899-7
De Gregorio, A., Pedrotti, E., Russo, L. & Morselli, S. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol, https://doi.org/10.1007/s10792-017-0571-x (2017).
doi: 10.1007/s10792-017-0571-x
Schlenker, M. B. et al. Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy. Ophthalmology 124, 1579–1588 (2017).
doi: 10.1016/j.ophtha.2017.05.004
Pérez-Torregrosa, V. T. et al. Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions. Arch Soc Esp Oftalmol 91, 415–421 (2016).
doi: 10.1016/j.oftal.2016.02.006
Buffault, J., Baudouin, C. & Labbé, A. XEN® Gel Stent for management of chronic open angle glaucoma: A review of the literature. J Fr Ophtalmol 42, e37–e46 (2019).
doi: 10.1016/j.jfo.2018.12.002
Galal, A., Bilgic, A., Eltanamly, R. & Osman, A. XEN Glaucoma Implant with Mitomycin C 1-Year Follow-Up: Result and Complications. J Ophthalmol 2017, 5457246 (2017).
pubmed: 28348884
pmcid: 5350531
Mansouri, K. et al. Prospective Evaluation of Standalone XEN Gel Implant and Combined Phacoemulsification-XEN Gel Implant Surgery: 1-Year Results. J. Glaucoma 27, 140–147 (2018).
doi: 10.1097/IJG.0000000000000858
Lachkar, Y. et al. Nonpenetrating deep sclerectomy: a 6-year retrospective study. Eur. J. Ophthalmol. 14, 26–36 (2004).
doi: 10.1177/112067210401400105
Gabbay, I. E. et al. Efficacy and safety data for the XEN45 implant at 2 years: a retrospective analysis. Br J Ophthalmol, https://doi.org/10.1136/bjophthalmol-2019-313870 (2019).
Esfandiari, H., Pakravan, M., Loewen, N. A. & Yaseri, M. Predictive value of early postoperative IOP and bleb morphology in Mitomycin-C augmented trabeculectomy. F1000Res 6 (2017).
Rong, S. S. et al. Can early postoperative intraocular pressure predict success following mitomycin-C augmented trabeculectomy in primary angle-closure glaucoma. Eye (Lond) 27, 403–409 (2013).
doi: 10.1038/eye.2012.291
Stewart, W. C. & Pitts, R. A. Postoperative prognostic indicators following trabeculectomy. Acta Ophthalmol. (Copenh) 71, 733–738 (1993).
doi: 10.1111/j.1755-3768.1993.tb08592.x
Karri, B., Gupta, C. & Mathews, D. Endophthalmitis Following XEN Stent Exposure. J. Glaucoma https://doi.org/10.1097/IJG.0000000000001012 (2018).
doi: 10.1097/IJG.0000000000001012
pubmed: 29952822
Gillmann, K., Bravetti, G. E., Mermoud, A. & Mansouri, K. Anterior Chamber XEN Gel Stent Movements: The Impact on Corneal Endothelial Cell Density. J. Glaucoma, https://doi.org/10.1097/IJG.0000000000001200 (2019).
doi: 10.1097/IJG.0000000000001200